A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii
Open Access
- 18 December 2023
- journal article
- review article
- Published by Wiley in Cancer Reports
- Vol. 7 (2) , e1963
Abstract
Background: Recently, immunotherapy has become very hopeful for cancer therapy. Cancer treatment through immunotherapy has excellent specificity and less toxicity than conventional chemoradiotherapy. Pathogens have been used in cancer immunotherapy for a long time. The current study aims to evaluate the possibility of Toxoplasma gondii (T. gondii) as a probable treatment for cancers such as melanoma, breast, ovarian, lung, and pancreatic cancer.Recent findings: Nonreplicating type I uracil auxotrophic mutants of T. gondii can stimulate immune responses against tumors by reverse immunosuppression at the cellular level. T. gondii can be utilized to research T helper 1 (Th1) cell immunity in intracellular infections. Avirulent T. gondii uracil auxotroph vaccine can change the tumor's immunosuppression and improve the production of type 1 helper cell cytokines, i.e., Interferon‐gamma (IFN‐γ) and Interleukin‐12 (IL‐12) and activate tumor‐related Cluster of Differentiation 8 (CD8+) T cells to identify and destroy cancer cells. The T. gondii profilin protein, along with T. gondii secreted proteins, have been found to exhibit promising properties in the treatment of various cancers. These proteins are being studied for their potential to inhibit tumor growth and enhance the effectiveness of cancer therapies. Their unique mechanisms of action make them valuable candidates for targeted interventions in ovarian cancer, breast cancer, pancreatic cancer, melanoma, and lung cancer treatments.Conclusion: In summary, the study underscores the significant potential of harnessing T. gondii, including its diverse array of proteins and antigens, particularly in its avirulent form, as a groundbreaking approach in cancer immunotherapy.Keywords
This publication has 153 references indexed in Scilit:
- Targeted therapy using nanotechnology: focus on cancerInternational Journal of Nanomedicine, 2014
- The Rhoptry Proteins ROP18 and ROP5 Mediate Toxoplasma gondii Evasion of the Murine, But Not the Human, Interferon-Gamma ResponsePLOS Pathogens, 2012
- An Inside Job: Hacking into Janus Kinase/Signal Transducer and Activator of Transcription Signaling Cascades by the Intracellular Protozoan Toxoplasma gondiiInfection and Immunity, 2012
- Innate responses to Toxoplasma gondii in mice and humansTrends in Parasitology, 2011
- Assessment of the Evolution of Cancer Treatment TherapiesCancers, 2011
- In situStimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer–Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory CellsCancer Research, 2009
- Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunityJournal of Clinical Investigation, 2009
- T cell expression of MyD88 is required for resistance toToxoplasma gondiiProceedings of the National Academy of Sciences, 2008
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like ProteinScience, 2005